+

WO2000030668A3 - Utilisation de particules de capsides de parvovirus dans l'inhibition de la proliferation et de la migration cellulaire - Google Patents

Utilisation de particules de capsides de parvovirus dans l'inhibition de la proliferation et de la migration cellulaire Download PDF

Info

Publication number
WO2000030668A3
WO2000030668A3 PCT/IB1999/002112 IB9902112W WO0030668A3 WO 2000030668 A3 WO2000030668 A3 WO 2000030668A3 IB 9902112 W IB9902112 W IB 9902112W WO 0030668 A3 WO0030668 A3 WO 0030668A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
parvovirus capsid
migration
inhibition
cell proliferation
Prior art date
Application number
PCT/IB1999/002112
Other languages
English (en)
Other versions
WO2000030668A2 (fr
WO2000030668A9 (fr
WO2000030668A8 (fr
Inventor
Kristina Broliden
Magnus Westgren
Original Assignee
Kristina Broliden
Magnus Westgren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020017006374A priority Critical patent/KR20010080518A/ko
Priority to HU0104298A priority patent/HUP0104298A2/hu
Priority to JP2000583551A priority patent/JP2003516927A/ja
Priority to MXPA01004949A priority patent/MXPA01004949A/es
Priority to AU25666/00A priority patent/AU2566600A/en
Priority to CA002352043A priority patent/CA2352043A1/fr
Priority to EP99968407A priority patent/EP1131085A2/fr
Application filed by Kristina Broliden, Magnus Westgren filed Critical Kristina Broliden
Publication of WO2000030668A2 publication Critical patent/WO2000030668A2/fr
Publication of WO2000030668A8 publication Critical patent/WO2000030668A8/fr
Publication of WO2000030668A3 publication Critical patent/WO2000030668A3/fr
Publication of WO2000030668A9 publication Critical patent/WO2000030668A9/fr
Priority to IS5931A priority patent/IS5931A/is
Priority to NO20012534A priority patent/NO20012534L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne la découverte de méthodes et de compositions permettant d'inhiber la croissance et/ou la migration de cellules porteuses de l'antigène P, notamment, entre autres, les cellules d'origine hématopoïétique et des cellules endothéliales. L'invention concerne, en particulier, l'utilisation de particules de capsides de parvovirus ou de fragments de protéines de capsides de parvovirus dans la fabrication de médicaments susceptibles d'être administrés à un patient dans le but d'inhiber la croissance des progéniteurs hématopoïétiques (par exemple, avant transplantation de cellules souches), la croissance des cellules endothéliales (par exemple, en tant que traitement anti-tumorigenèse ou pour empêcher la resténose ou l'accumulation de fibres après implantation d'une prothèse) ou pour empêcher les troubles impliquant la prolifération anormale de cellules porteuses de l'antigène P (par exemple, la polyglobuline essentielle).
PCT/IB1999/002112 1998-11-24 1999-11-23 Utilisation de particules de capsides de parvovirus dans l'inhibition de la proliferation et de la migration cellulaire WO2000030668A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
HU0104298A HUP0104298A2 (hu) 1998-11-24 1999-11-23 Parvovíruskapszid-részecskék alkalmazása a sejtproliferáció és -migráció gátlására
JP2000583551A JP2003516927A (ja) 1998-11-24 1999-11-23 細胞増殖および移動の抑制におけるパルボウイルスキャプシド粒子の使用
MXPA01004949A MXPA01004949A (es) 1998-11-24 1999-11-23 Uso de particulas de capside de parvovirus en la inhibicion de la proliferacion y la migracion celular.
AU25666/00A AU2566600A (en) 1998-11-24 1999-11-23 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
CA002352043A CA2352043A1 (fr) 1998-11-24 1999-11-23 Utilisation de particules de capsides de parvovirus dans l'inhibition de la proliferation et de la migration cellulaire
KR1020017006374A KR20010080518A (ko) 1998-11-24 1999-11-23 세포 증식 및 세포 이동의 억제에 대한 파르보바이러스캡시드 입자의 용도
EP99968407A EP1131085A2 (fr) 1998-11-24 1999-11-23 Utilisation de particules de capsides de parvovirus dans l'inhibition de la proliferation et de la migration cellulaire
IS5931A IS5931A (is) 1998-11-24 2001-05-02 Notkun smáveiruhjúphluta til að hamla frumufjölgun og frumuflutningi
NO20012534A NO20012534L (no) 1998-11-24 2001-05-23 Anvendelse av parvoviruskapsidpartikler ved inhiberingen av celleproliferering og migrering

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9804022-3 1998-11-24
SE9804022A SE520177C2 (sv) 1998-11-24 1998-11-24 Användning av tomma, icke-infektiösa, rekombinanta parvoviruskapsidpartiklar, eller P-antigenblockerande delar därav, för framställning av läkemedel för ihibering av hematopoietiska stamceller

Publications (4)

Publication Number Publication Date
WO2000030668A2 WO2000030668A2 (fr) 2000-06-02
WO2000030668A8 WO2000030668A8 (fr) 2000-09-14
WO2000030668A3 true WO2000030668A3 (fr) 2000-11-09
WO2000030668A9 WO2000030668A9 (fr) 2001-04-05

Family

ID=20413393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1999/002112 WO2000030668A2 (fr) 1998-11-24 1999-11-23 Utilisation de particules de capsides de parvovirus dans l'inhibition de la proliferation et de la migration cellulaire

Country Status (14)

Country Link
EP (1) EP1131085A2 (fr)
JP (1) JP2003516927A (fr)
KR (1) KR20010080518A (fr)
CN (1) CN1328469A (fr)
AU (1) AU2566600A (fr)
CA (1) CA2352043A1 (fr)
CZ (1) CZ20011369A3 (fr)
HU (1) HUP0104298A2 (fr)
IS (1) IS5931A (fr)
MX (1) MXPA01004949A (fr)
NO (1) NO20012534L (fr)
PL (1) PL348640A1 (fr)
SE (1) SE520177C2 (fr)
WO (1) WO2000030668A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE345352T1 (de) 2001-07-10 2006-12-15 Deutsches Krebsforsch Zusammensetzung einer parvovirus vp1- proteinvariante und eines arvovirus ns1-proteins zur induktion von zytolyse
WO2006032697A2 (fr) * 2004-09-24 2006-03-30 Intercell Ag Parvovirus
CN101475942B (zh) * 2008-11-28 2012-05-23 中国人民解放军第四军医大学 一种b19病毒vp1独特区基因
US9598468B2 (en) 2011-05-18 2017-03-21 University Of Florida Research Foundation, Incorporated Polypeptides and vectors for targeting HER2/neu expressing cells and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004330A1 (fr) * 1989-09-14 1991-04-04 Rijksuniversiteit Te Leiden Proteines du parvovirus b19 humain et particules d'aspect viral, leur production et leur utilisation dans les analyses diagnostiques et les vaccins
US5508186A (en) * 1988-11-14 1996-04-16 The United States Of America As Represented By The Secretary Of Health And Human Services B19 parvovirus capsids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508186A (en) * 1988-11-14 1996-04-16 The United States Of America As Represented By The Secretary Of Health And Human Services B19 parvovirus capsids
WO1991004330A1 (fr) * 1989-09-14 1991-04-04 Rijksuniversiteit Te Leiden Proteines du parvovirus b19 humain et particules d'aspect viral, leur production et leur utilisation dans les analyses diagnostiques et les vaccins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MORTIMER P P ET AL.: "A human parvovirus-like virus inhibits haematopoietic colony formation in vitro", NATURE, vol. 302, 31 March 1983 (1983-03-31), pages 426 - 429, XP002140633 *
SHIELDS L E ET AL: "In vitro hematopoiesis is inhibited in humans and non-human primates by recombinant parvo virus capsid.", AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, vol. 182, no. 1 Part 2, January 2000 (2000-01-01), 20th Annual Meeting of the Society for Maternal-Fetal Medicine.;Miami Beach, Florida, USA; January 31-February 05, 2000, pages S18, XP000914833 *

Also Published As

Publication number Publication date
CN1328469A (zh) 2001-12-26
WO2000030668A2 (fr) 2000-06-02
MXPA01004949A (es) 2003-03-10
JP2003516927A (ja) 2003-05-20
HUP0104298A2 (hu) 2002-03-28
WO2000030668A9 (fr) 2001-04-05
SE9804022L (sv) 2000-05-25
NO20012534L (no) 2001-06-29
SE520177C2 (sv) 2003-06-03
CA2352043A1 (fr) 2000-06-02
EP1131085A2 (fr) 2001-09-12
AU2566600A (en) 2000-06-13
CZ20011369A3 (cs) 2001-10-17
NO20012534D0 (no) 2001-05-23
IS5931A (is) 2001-05-02
KR20010080518A (ko) 2001-08-22
PL348640A1 (en) 2002-06-03
WO2000030668A8 (fr) 2000-09-14
SE9804022D0 (sv) 1998-11-24

Similar Documents

Publication Publication Date Title
Deng et al. Bioceramic scaffolds with antioxidative functions for ROS scavenging and osteochondral regeneration
Lynn et al. Temporal progression of the host response to implanted poly (ethylene glycol)‐based hydrogels
WO1999046366A8 (fr) Utilisations de cellules souches humaines mesenchymateuses non autologues
AU4221399A (en) Human cd45+ and/or fibroblast + mesenchymal stem cells
UA81398C2 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
BR0315645A (pt) Polipetìdeos de fusão de actrib e seus usos
WO2003059276A3 (fr) Nouvelles cellules souches multipotentes d'origine mammalienne, methodes de preparation et methodes d'administration desdites cellules
AU4035199A (en) Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation
NZ527565A (en) Methods and devices for tissue repair
YU57701A (sh) Veštački peptidi koji imaju površinsku aktivnost i njihova upotreba u pripremi veštačkog surfaktanta
WO1998033509A3 (fr) Proprietes utiles de la lactoferrine humaine et de variants de celle-ci
WO2003068149A3 (fr) Preparations de cellules du nucleus pulposus et procedes permettant leur generation, identification, et utilisation
WO2002069988A3 (fr) Compositions contenant des cellules de moelle osseuse ainsi qu'une matrice osseuse demineralisee et/ou mineralisee et leur utilisation dans la transplantation de moelle osseuse
Fan et al. Placenta‐versus bone‐marrow‐derived mesenchymal cells for the repair of segmental bone defects in a rabbit model
DE69726759D1 (de) Cytopatische viren zur therapie und prophylaxe der neoplasie
IL115473A (en) Pharmaceutical compositions and compounds for inhibition of stem cell proliferation, use of such compounds in the manufacture of medicaments for this purpose, and in vitro methods for treating bone marrow and for preparing hematopoietic cells for therapy
AU2901899A (en) 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
Rakonczay Jr et al. Chronic inflammation in the pancreas and salivary glands-lessons from similarities and differences in pathophysiology and treatment modalities
WO2000030668A3 (fr) Utilisation de particules de capsides de parvovirus dans l'inhibition de la proliferation et de la migration cellulaire
LTIP610A (en) Inhibitors of cells proliferation, pharmaceutical composition and method for preparation of compounds
WO2003102162A3 (fr) Nouvelles cellules dendritiques tolerogeniques et utilisations therapeutiques de celles-ci
DE69900495D1 (de) Flüssigkristalle des cyclosporins
WO2001070290A3 (fr) Microspheres injectables destinees a la construction de tissus
DE60020727D1 (de) Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
Kim et al. Osteogenesis for postoperative temporal bone defects using human ear adipose‐derived stromal cells and tissue engineering: an animal model study

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99813653.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGE 1, DESCRIPTION, REPLACED BY A NEW PAGE 1; PAGES 1/8-8/8, DRAWINGS, REPLACED BY NEW PAGES 1/8-8/8; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 142602

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2001-1369

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 511402

Country of ref document: NZ

Ref document number: 25666/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/004949

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020017006374

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2352043

Country of ref document: CA

Ref document number: 2352043

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 583551

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999968407

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017006374

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999968407

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-1369

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV2001-1369

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020017006374

Country of ref document: KR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载